| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 91,92 | 94,18 | 14:47 | |
| 93,14 | 94,06 | 14:47 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 96,00 | 2.000 | |||
| 95,90 | 120 | |||
| 95,00 | 120 | |||
| 94,56 | 200 | |||
| 94,48 | 44 | |||
| 94,38 | 186 | |||
| 94,34 | 1 | |||
| 94,24 | 100 | |||
| 94,20 | 98 | |||
| 94,16 | 84 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/ewl.htm [/URL] | ||||
| 98 | 91,92 | |||
| 100 | 91,90 | |||
| 98 | 91,88 | |||
| 100 | 91,72 | |||
| 90 | 91,70 | |||
| 86 | 91,64 | |||
| 1 | 91,62 | |||
| 84 | 91,58 | |||
| 400 | 91,20 | |||
| 252 | 91,04 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.309 | 2,256 | 2.953 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 10.11.2026 | 13:37:44 | 93,96 | 5 |
| 10.11.2026 | 13:37:44 | 93,54 | 20 |
| Tagesumsatz Xetra | +0,54 +0,58 % | 50 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Edwards Lifesciences stock rating maintained at Buy by TD Cowen | 4 | Investing.com | ||
| Do | Wells Fargo raises Edwards Lifesciences price target on Q3 beat | 11 | Investing.com | ||
| EDWARDS LIFESCIENCES Aktie jetzt für 0€ handeln | |||||
| Do | Mizuho raises Edwards Lifesciences stock price target on TAVR beat | 5 | Investing.com | ||
| Do | Edwards Lifesciences: Mizuho hebt Kursziel nach überzeugenden TAVR-Zahlen an | 2 | Investing.com Deutsch | ||
| Do | Edwards Lifesciences CEO says 'more competition is coming' in TAVR | 25 | MassDevice |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 09:54 | DEUTSCHE BANK RESEARCH stuft NOVO NORDISK auf 'Sell' | dpa-AFX-Analyser | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novo Nordisk nach einem genaueren Blick auf die Resultate des dritten Quartals mit einem Kursziel von 240 dänischen Kronen... ► Artikel lesen | |
| 12:36 | Compass Pathfinder Limited: Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th | Business Wire | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies... ► Artikel lesen | |
| 12:10 | Boehringer Ingelheim: The savings that cost more: new report puts a number on Europe's innovation choice | GlobeNewswire (Europe) | This release is intended for the general public, healthcare professionals, policymakers and other healthcare decision-makers, plus pharmaceutical, policy and trade media.
New analysis of five EU... ► Artikel lesen | |
| 10:34 | Novo Nordisk A/S: Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and care | GlobeNewswire (Europe) | Bagsværd, Denmark, 11 November 2026 - Novo Nordisk today announced a USD 200 million commitment to the World Diabetes Foundation (WDF) for 2027-2036. Announced ahead of World Diabetes Day (14 November)... ► Artikel lesen | |
| 13:34 | Teva Pharmaceutical Industries Ltd: Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6-7 Billion in Innovative Medicines Revenue by 2030 | GlobeNewswire (Europe) | The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma... ► Artikel lesen |